Hemispherx Biopharma (HEB) Summarizes Clinical Results Presented In Washington, DC On January 30, 2014 In Conjunction With The American Society for Microbiology Biodefense Conference Aimed At Developing A Universal Influenza Vaccine To Prevent Pandemic Influenza Threat
2/4/2014 9:04:51 AM
PHILADELPHIA, Feb. 4, 2014 (GLOBE NEWSWIRE) -- Hemispherx Biopharma, Inc. (NYSE MKT:HEB) (the "Company" or "Hemispherx"), presented a summary of the results of its Phase I/II study from the poster presentation entitled "Seasonal Influenza Vaccine and a TLR-3 Agonist, Rintatolimod (Ampligen®), Given Intranasally Produced Cross-Reactive IgA Antibodies Against Pathogenic H5N1 Influenza HA" given at the American Society for Microbiology (ASM) Biodefense Conference in Washington, DC on January 30, 2014.
Help employers find you! Check out all the jobs and post your resume.
comments powered by